선도연구센터 (Leading Research Center: Cellular Responses to Metabolic Stress Research Center)
Supported by National Research Foundation of Korea (Period: 2018-2025, Total support: KRW10,500,000,000) Director: Prof. Hyug Moo Kwon Participants: Profs. Byoung Heon Kang, Chan Young Park, Ji Young Park, Jang Hyun Choi, Ha Jin Kim and Sung Ho Park Center Goals: The metabolic stress is the causative factor related deeply to 7 diseases out of the highest 10 death-causing diseases in Korea people. The basic research will provide a groundbreaking clue to develop new treatments.
과기원 공동연구단 (Joint Research Group in Institutes of science and technology: Developing the treatment drug for COVID-19 based on artificial intelligence technologies)
Supported by Joint Research Group in Institutes of science and technology (Period: 2020-2024, Total support: KRW5,500,000,000) Director: Prof. Hyug Moo Kwon Participants: Profs. Chan Young Park, Chang Wook Lee Center Goals is to develop the treatment drug for SARS-CoV2 and COVID-19 using artificial intelligence in order not to infect millions of people worldwide.
중점연구소 (Key Research Institutes in University)
중점연구소 (Key Research Institutes in University) Name: Center for Cell-to-Cell Communication in Cancers (The C5 Center) Supported by National Research Foundation of Korea (KNRF) and Ulsan City (Period: 2018-2027, Total support: KRW5,900,000,000) Director: Prof. Sebyung Kang Participants: Profs. HyungJoon Cho, Myunggon Ko, Eunhee Kim, Young Chan Chae, Taejoon Kwon, and Semin Lee Center Goals: The C5 center’s research focuses on the elucidation of the tumor microenvironment (TME) composed of heterogeneous cancer cells and their complexed neighboring cells including normal surrounding cells and immune cells. The members of the center are collaboratively working on figuring out the fundamental mechanism of the tumor microenvironment and applying our basic knowledge translationally not only to diagnose the caner as early as possible but also to properly control the TME to cure many intractable cancers with newly developed therapeutic candidates.